Kintor Pharmaceutical Limited (HKEX: 9939), a China-based clinical-stage biotechnology company, announced on Wednesday that it has dosed the first batch of subjects in its phase one clinical trial of GT20029 in China.
The phase I trial, a randomised, double-blind, placebo-controlled study, is intended to assess the safety, tolerability, and pharmacokinetics of the product (gel/tincture) subsequent to the topical single and multiple ascending dose administration in healthy patients.
According to Kintor Pharmaceutical, the product is the first topical Proteolysis Targeting Chimera compound globally to enter the clinical stage. It received approval from The China Center for Drug Evaluation (CDE) and the US Food and Drug Administration (FDA) for phase one clinical trial for treating androgenetic alopecia and acne in April 2021 and July 2021 separately.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial